US researchers have reviewed 25 trials and studies to evaluate the benefits and harms of cannabinoids for chronic pain.
Cannabidiol use seems to be increasing, with a recent University of Sydney study showing around 55,000 requests to access medicinal CBD approved since 2016.
In 2020, drug-induced deaths were nearly twice as frequent among males as females, according to a new report by the National Drug and Alcohol Research Centre.
Despite the discomfort, only 11% of people would see an optometrist and only around 3% would speak to a pharmacist for advice.
Around 248,000 medicinal cannabis scripts have been approved in Australia since 2016, and the drug is increasingly prescribed for various conditions, reveals a new study.
The Australian Commission on Safety and Quality in Health Care has launched a new national standard for opioid analgesics to help prevent long-term harm.
Researchers from the University of South Australia are working with European researchers to investigate a range of FDA-approved drugs with an aim to help kids with severe epilepsy.
The SHPA has welcomed the medicines agreements as vital to protecting patients against shortages and ensuring medicines are accessible, available and cost-efficient.
The Australian Commission on Safety and Quality in Health Care is seeking comments on the draft clinical care standard for opioid analgesics.
Australia needs a comprehensive, coordinated approach to overdose prevention by national and state governments and professional groups.
The smartphone-based pain assessment application has potential for use in children's hospitals, in postnatal wards, and among parents and other healthcare professionals.
This fortnight is the last chance for aged-care facilities to participate in the government-subsidised rollout of a complete point-of-care solution for best practice pain management.
The Avalon Study has demonstrated the life-changing benefits of a closed-loop spinal cord stimulation system in patients with chronic, intractable pain.
Patients with low back pain have been shown to respond well to NSAIDs such as ibuprofen, according to researchers at RMIT University.
ShotBlocker is a non-invasive solution that has been shown to reduce or remove pain in 93.2% of users at half the cost of topical freezing sprays and anaesthetic creams.